{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T13:12:21Z","timestamp":1789823541852,"version":"4.0.1"},"reference-count":46,"publisher":"Walter de Gruyter GmbH","issue":"2","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Long-term survivors of childhood malignancies are at increased risk of experiencing treatment-related morbidities. Survival into late adulthood in these children provides ample time for the acquisition of long-term sequelae. This study aimed to determine the late adverse effects among long-term survivors of childhood cancer from a low-income country perspective.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>Data were retrospectively collected from review of charts of patients aged under 18 years at the time of their primary diagnosis between 1 January, 1995, and 31 December, 2008, and who survived for at least 5 years after completion of their treatment. Analysed data included demographics, cancer type, treatment modality, types of chemotherapy agents administered and specific late morbidities including frequency of azoospermia, oligospermia, endocrine abnormalities, hearing and pulmonary function impairment and cardiac dysfunction among the long-term survivors of cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The total number of patients was 300 with a mean age of 18 \u00b1 2 years. The male to female ratio was 2.7:1. Median follow-up duration was 18 years (range: 5\u201325 years). Seventy-seven percent of patients were from Punjab, 20% were from Khyber Pakhtunkhwa and 3% were from other provinces. Fifty percent had a diagnosis of Hodgkin lymphoma, 17% had acute lymphoblastic leukaemia, 13% had non-Hodgkin lymphoma, 10% had germ cell tumours and 10% had other tumours. Fifty-seven percent received chemotherapy, 23% had chemotherapy and radiotherapy, 15% had chemotherapy and surgery, 3% had chemotherapy, surgery and radiotherapy and 2% had only surgery. Notable long-term documented sequelae were; azoospermia\/oligospermia in 64%, endocrine abnormalities in 25% with hypothyroidism in 13.5% and follicle-stimulating hormone and luteinizing hormone abnormalities in 11.5%, ototoxicity in 6.5%, impaired pulmonary function tests in 4.6%, cardiotoxicity in 2.4% and second malignancies (acute myeloid leukaemia and myelodysplastic syndrome) in 1%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Childhood cancer survivors are at increased risk of adverse treatment-related sequelae and a long-term follow-up plan should be in place in centres where they receive treatment for their primary disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.37029\/jcas.v6i2.351","type":"journal-article","created":{"date-parts":[[2020,7,6]],"date-time":"2020-07-06T04:57:36Z","timestamp":1594011456000},"page":"1-9","source":"Crossref","is-referenced-by-count":2,"title":["Late Morbidity among Survivors of Childhood Cancers; Experience at Tertiary Care Cancer Hospital"],"prefix":"10.2478","volume":"6","author":[{"given":"Najma","family":"Shaheen","sequence":"first","affiliation":[{"name":"Department of Pediatric Oncology , Shaukat Khanum Memorial Cancer Hospital and Research Centre , Lahore , Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mir Rooh Ullah","family":"Jan","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology , Shaukat Khanum Memorial Cancer Hospital and Research Centre , Lahore , Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shazia","family":"Riaz","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology , Shaukat Khanum Memorial Cancer Hospital and Research Centre , Lahore , Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Saghir","family":"Khan","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology , Shaukat Khanum Memorial Cancer Hospital and Research Centre , Lahore , Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2020,7,6]]},"reference":[{"key":"2026091912311761058_j_jcas.v6i2.351_ref_001","doi-asserted-by":"crossref","unstructured":"Ward E, DeSantis C, Robbins A, Kohler B, Jemal A. Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin 2014;64:83-103.","DOI":"10.3322\/caac.21219"},{"key":"2026091912311761058_j_jcas.v6i2.351_ref_002","doi-asserted-by":"crossref","unstructured":"Friedman DL, Meadows AT. Late effects of childhood cancer therapy. Pediatr Clin North Am 2002;49:1083-6.","DOI":"10.1016\/S0031-3955(02)00032-9"},{"key":"2026091912311761058_j_jcas.v6i2.351_ref_003","doi-asserted-by":"crossref","unstructured":"Wolden SL, Chen L, Kelly KM, Herzog P, Gilchrist GS, Thomson J, et al. Long-term results of CCG 5942: A randomized comparison of chemotherapy with and without radiotherapy for children with Hodgkin\u2019s lymphoma-a report from the children\u2019s oncology group. J Clin Oncol 2012;30:3174-80.","DOI":"10.1200\/JCO.2011.41.1819"},{"key":"2026091912311761058_j_jcas.v6i2.351_ref_004","doi-asserted-by":"crossref","unstructured":"Robison LL, Hudson MM. Survivors of childhood and adolescent cancer: Life-long risks and responsibilities. Nat Rev Cancer 2014;14:61-70.","DOI":"10.1038\/nrc3634"},{"key":"2026091912311761058_j_jcas.v6i2.351_ref_005","unstructured":"Sloan FA, Gelband H. The cancer burden in low-and middle-income countries and how it is measured. In: Cancer Control Opportunities in Low-and Middle-Income Countries 2007. United States: National Academies Press; 2007."},{"key":"2026091912311761058_j_jcas.v6i2.351_ref_006","doi-asserted-by":"crossref","unstructured":"Cairo MS, Gerrard M, Sposto R, Auperin A, Pinkerton CR, Michon J, et al. Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. Blood 2007;109:2736-43.","DOI":"10.1182\/blood-2006-07-036665"},{"key":"2026091912311761058_j_jcas.v6i2.351_ref_007","doi-asserted-by":"crossref","unstructured":"Gerrard M, Cairo MS, Weston C, Auperin A, Pinkerton R, Lambilliote A, et al. Excellent survival following two courses of COPAD chemotherapy in children and adolescents with resected localized B-cell non-Hodgkin\u2019s lymphoma: Results of the FAB\/LMB 96 international study. Br J Haematol 2008;141:840-7.","DOI":"10.1111\/j.1365-2141.2008.07144.x"},{"key":"2026091912311761058_j_jcas.v6i2.351_ref_008","doi-asserted-by":"crossref","unstructured":"Hann I, Vora A, Harrison G, Harrison C, Eden O, Hill F, et al. Determinants of outcome after intensified therapy of childhood lymphoblastic leukaemia: Results from medical research council United Kingdom acute lymphoblastic leukaemia XI protocol. Br J Haematol 2001;113:103-14.","DOI":"10.1046\/j.1365-2141.2001.02668.x"},{"key":"2026091912311761058_j_jcas.v6i2.351_ref_009","doi-asserted-by":"crossref","unstructured":"Vora A, Goulden N, Wade R, Mitchell C, Hancock J, Hough R, et al. Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): A randomised controlled trial. Lancet Oncol 2013;14:199-209.","DOI":"10.1016\/S1470-2045(12)70600-9"},{"key":"2026091912311761058_j_jcas.v6i2.351_ref_010","doi-asserted-by":"crossref","unstructured":"Friedman DL, Himelstein B, Shields CL, Shields JA, Needle M, Miller D, et al. Chemoreduction and local ophthalmic therapy for intraocular retinoblastoma. J Clin Oncol 2000;18:12-7.","DOI":"10.1200\/JCO.2000.18.1.12"},{"key":"2026091912311761058_j_jcas.v6i2.351_ref_011","doi-asserted-by":"crossref","unstructured":"Mann JR, Raafat F, Robinson K, Imeson J, Gornall P, Phillips M, et al. UKCCSG\u2019s germ cell tumour (GCT) studies: Improving outcome for children with malignant extracranial non-gonadal tumourscarboplatin, etoposide, and bleomycin are effective and less toxic than previous regimens. United Kingdom children\u2019s cancer study group. Med Pediatr Oncol 1998;30:217-27.","DOI":"10.1002\/(SICI)1096-911X(199804)30:4<217::AID-MPO3>3.0.CO;2-J"},{"key":"2026091912311761058_j_jcas.v6i2.351_ref_012","doi-asserted-by":"crossref","unstructured":"Graf N, Tournade MF, de Kraker J. The role of preoperative chemotherapy in the management of Wilms\u2019 tumor: The SIOP studies. International society of pediatric oncology. Urol Clin North Am 2000;27:443-54.","DOI":"10.1016\/S0094-0143(05)70092-6"},{"key":"2026091912311761058_j_jcas.v6i2.351_ref_013","doi-asserted-by":"crossref","unstructured":"Green DM. The treatment of stages I-IV favorable histology Wilms\u2019 tumor. J Clin Oncol 2004;22:1366-72.","DOI":"10.1200\/JCO.2004.08.008"},{"key":"2026091912311761058_j_jcas.v6i2.351_ref_014","unstructured":"K\u00f6rholz D, Hamish W. Radiotherapy Manual; 2020. Available from: https:\/\/www.skion.nl\/workspace\/uploads\/euronet-phl-c1_workingcopy_inkl_ amendm06_mw_2012-11-14_0.pdf. [Last accessed on 2020 May 01]."},{"key":"2026091912311761058_j_jcas.v6i2.351_ref_015","doi-asserted-by":"crossref","unstructured":"Hann I, Vora A, Richards S, Hill F, Gibson B, Lilleyman J, et al. Benefit of intensified treatment for all children with acute lymphoblastic leukaemia: Results from MRC UKALL XI and MRC ALL97 randomised trials. UK medical research council\u2019s working party on childhood leukaemia. Leukemia 2000;14:356-63.","DOI":"10.1038\/sj.leu.2401704"},{"key":"2026091912311761058_j_jcas.v6i2.351_ref_016","doi-asserted-by":"crossref","unstructured":"Coppes MJ, Wolff JE, Ritchey ML. Wilms tumour: Diagnosis and treatment. Paediatr Drugs 1999;1:251-62.","DOI":"10.2165\/00128072-199901040-00002"},{"key":"2026091912311761058_j_jcas.v6i2.351_ref_017","unstructured":"World Health Organization. Prevention of Blindness and Deafness: Grades of Hearing Impairment. Geneva: World Health Organization; 2011. Available from: http:\/\/www.who.int\/pbd\/deafness\/hearing_impairment_grades\/en\/index.html. [Last accessed on 2011 July 01]."},{"key":"2026091912311761058_j_jcas.v6i2.351_ref_018","doi-asserted-by":"crossref","unstructured":"MacIntyre N, Crapo R, Viegi G, Johnson DC, van der Grinten CP, Brusasco V, et al. Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J 2005;26:720-35.","DOI":"10.1183\/09031936.05.00034905"},{"key":"2026091912311761058_j_jcas.v6i2.351_ref_019","doi-asserted-by":"crossref","unstructured":"Kapelari K, Kirchlechner C, H\u00f6gler W, Schweitzer K, Virgolini I, Moncayo R. Pediatric reference intervals for thyroid hormone levels from birth to adulthood: A retrospective study. BMC Endocr Disord 2008;8:15.","DOI":"10.1186\/1472-6823-8-15"},{"key":"2026091912311761058_j_jcas.v6i2.351_ref_020","doi-asserted-by":"crossref","unstructured":"Langer T, Grabow D, Steinmann D, W\u00f6rmann B, Calaminus G. Late effects and long-term follow-up after cancer in childhood. Oncol Res Treat 2017;40:746-50.","DOI":"10.1159\/000484936"},{"key":"2026091912311761058_j_jcas.v6i2.351_ref_021","doi-asserted-by":"crossref","unstructured":"Livinalli A, Silva MT, Lopes LC. Late adverse effects related to treatment in a cohort of survivors of childhood and adolescent cancer. Medicine (Baltimore) 2019;98:e14921.","DOI":"10.1097\/MD.0000000000014921"},{"key":"2026091912311761058_j_jcas.v6i2.351_ref_022","doi-asserted-by":"crossref","unstructured":"Travis LB, Hill DA, Dores GM, Gospodarowicz M, van Leeuwen FE, Holowaty E, et al. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA 2003;290:465-75.","DOI":"10.1001\/jama.290.4.465"},{"key":"2026091912311761058_j_jcas.v6i2.351_ref_023","doi-asserted-by":"crossref","unstructured":"Temming P, Arendt M, Viehmann A, Eisele L, Le Guin CH, Sch\u00fcndeln MM, et al. Incidence of second cancers after radiotherapy and systemic chemotherapy in heritable retinoblastoma survivors: A report from the German reference center. Pediatr Blood Cancer 2017;64:71-80.","DOI":"10.1002\/pbc.26193"},{"key":"2026091912311761058_j_jcas.v6i2.351_ref_024","doi-asserted-by":"crossref","unstructured":"Chojnacka M, P\u0119dziwiatr K, Skowro\u0144ska-Gardas A, Perek-Polnik M, Perek D, Olasek P. Second brain tumors following central nervous system radiotherapy in childhood. Br J Radiol 2014;87:20140211.","DOI":"10.1259\/bjr.20140211"},{"key":"2026091912311761058_j_jcas.v6i2.351_ref_025","doi-asserted-by":"crossref","unstructured":"Friedman DL, Whitton J, Leisenring W, Mertens AC, Hammond S, Stovall M, et al. Subsequent neoplasms in 5-year survivors of childhood cancer: The childhood cancer survivor study. J Natl Cancer Inst 2010;102:1083-95.","DOI":"10.1093\/jnci\/djq238"},{"key":"2026091912311761058_j_jcas.v6i2.351_ref_026","doi-asserted-by":"crossref","unstructured":"Teepen JC, Kremer L, Ronckers CM, Van Leeuwen FE, Hauptmann M, Broeder VD, et al. Long-term risk of subsequent malignant neoplasms after treatment of childhood cancer in the DCOG LATER study cohort: Role of chemotherapy. J Clin Oncol 2017;35:2288-98.","DOI":"10.1200\/JCO.2016.71.6902"},{"key":"2026091912311761058_j_jcas.v6i2.351_ref_027","doi-asserted-by":"crossref","unstructured":"Maule M, Sc\u00e9lo G, Pastore G, Brennan P, Hemminki K, Tracey E, et al. Risk of second malignant neoplasms after childhood leukemia and lymphoma: An international study. J Natl Cancer Inst 2007;99:790-800.","DOI":"10.1093\/jnci\/djk180"},{"key":"2026091912311761058_j_jcas.v6i2.351_ref_028","doi-asserted-by":"crossref","unstructured":"Wasilewski-Masker K, Seidel KD, Leisenring W, Mertens AC, Shnorhavorian M, Ritenour CW, et al. Male infertility in long-term survivors of pediatric cancer: A report from the childhood cancer survivor study. J Cancer Surviv 2014;8:437-47.","DOI":"10.1007\/s11764-014-0354-6"},{"key":"2026091912311761058_j_jcas.v6i2.351_ref_029","doi-asserted-by":"crossref","unstructured":"van Casteren NJ, van der Linden GH, Hakvoort-Cammel FG, H\u00e4hlen K, Dohle GR, van den Heuvel-Eibrink MM. Effect of childhood cancer treatment on fertility markers in adult male long-term survivors. Pediatr Blood Cancer 2009;52:108-12.","DOI":"10.1002\/pbc.21780"},{"key":"2026091912311761058_j_jcas.v6i2.351_ref_030","doi-asserted-by":"crossref","unstructured":"Da Cunha MF, Meistrich ML, Fuller LM, Cundiff JH, Hagemeister FB, Velasquez WS, et al. Recovery of spermatogenesis after treatment for Hodgkin\u2019s disease: Limiting dose of MOPP chemotherapy. J Clin Oncol 1984;2:571-7.","DOI":"10.1200\/JCO.1984.2.6.571"},{"key":"2026091912311761058_j_jcas.v6i2.351_ref_031","doi-asserted-by":"crossref","unstructured":"Buchanan JD, Fairley KF, Barrie JU. Return of spermatogenesis after stopping cyclophosphamide therapy. Lancet 1975;306:156-7.","DOI":"10.1016\/S0140-6736(75)90059-8"},{"key":"2026091912311761058_j_jcas.v6i2.351_ref_032","doi-asserted-by":"crossref","unstructured":"Ramjaun A, AlDuhaiby E, Ahmed S, Wang L, Yu E, Nathan PC, et al. Echocardiographic detection of cardiac dysfunction in childhood cancer survivors: How long is screening required? Pediatr Blood Cancer 2015;62:2197-203.","DOI":"10.1002\/pbc.25651"},{"key":"2026091912311761058_j_jcas.v6i2.351_ref_033","doi-asserted-by":"crossref","unstructured":"Mulrooney DA, Armstrong GT, Huang S, Ness KK, Ehrhardt MJ, Joshi VM, et al. Cardiac outcomes in adult survivors of childhood cancer exposed to cardiotoxic therapy: A cross-sectional study from the St. Jude lifetime cohort. Ann Intern Med 2016;164:93-101.","DOI":"10.7326\/M15-0424"},{"key":"2026091912311761058_j_jcas.v6i2.351_ref_034","doi-asserted-by":"crossref","unstructured":"Hu H, Zhang W, Huang D, Yang Q, Li J, Gao Y. Cardiotoxicity of anthracycline (ANT) treatment in children with malignant tumors. Pediatr Hematol Oncol 2018;35:111-20.","DOI":"10.1080\/08880018.2018.1459983"},{"key":"2026091912311761058_j_jcas.v6i2.351_ref_035","doi-asserted-by":"crossref","unstructured":"Kasteler R, Weiss A, Schindler M, Sommer G, Latzin P, von der Weid NX, et al. Long-term pulmonary disease among Swiss childhood cancer survivors. Pediatr Blood Cancer 2018;65:e26749.","DOI":"10.1002\/pbc.27255"},{"key":"2026091912311761058_j_jcas.v6i2.351_ref_036","doi-asserted-by":"crossref","unstructured":"Huang TT, Hudson MM, Stokes DC, Krasin MJ, Spunt SL, Ness KK. Pulmonary outcomes in survivors of childhood cancer: A systematic review. Chest 2011;140:881-901.","DOI":"10.1378\/chest.10-2133"},{"key":"2026091912311761058_j_jcas.v6i2.351_ref_037","doi-asserted-by":"crossref","unstructured":"Sklar C, Whitton J, Mertens A, Stovall M, Green D, Marina N, et al. Abnormalities of the thyroid in survivors of Hodgkin\u2019s disease: Data from the childhood cancer survivor study. J Clin Endocrinol Metab 2000;85:3227-32.","DOI":"10.1210\/jcem.85.9.6808"},{"key":"2026091912311761058_j_jcas.v6i2.351_ref_038","doi-asserted-by":"crossref","unstructured":"Vogelius IR, Bentzen SM, Maraldo MV, Petersen PM, Specht L. Risk factors for radiation-induced hypothyroidism: A literature-based meta-analysis. Cancer 2011;117:5250-60.","DOI":"10.1002\/cncr.26186"},{"key":"2026091912311761058_j_jcas.v6i2.351_ref_039","doi-asserted-by":"crossref","unstructured":"Travis LB, Fossa SD, Sesso HD, Frisina RD, Herrmann DN, Beard CJ, et al. Chemotherapy-induced peripheral neurotoxicity and ototoxicity: New paradigms for translational genomics. J Natl Cancer Inst 2014;106:dju044.","DOI":"10.1093\/jnci\/dju044"},{"key":"2026091912311761058_j_jcas.v6i2.351_ref_040","doi-asserted-by":"crossref","unstructured":"Shimoda S, Horsman J, Furlong W, Barr R, de Camargo B. Disability and health-related quality of life in long-term survivors of cancer in childhood in Brazil. J Pediatr Hematol Oncol 2008;30:563-70.","DOI":"10.1097\/MPH.0b013e31816e231c"},{"key":"2026091912311761058_j_jcas.v6i2.351_ref_041","doi-asserted-by":"crossref","unstructured":"Bava L, Johns A, Kayser K, Freyer DR. Cognitive outcomes among Latino survivors of childhood acute lymphoblastic leukemia and lymphoma: A cross-sectional cohort study using culturally competent, performance-based assessment. Pediatr Blood Cancer 2018;65:e26844.","DOI":"10.1002\/pbc.26844"},{"key":"2026091912311761058_j_jcas.v6i2.351_ref_042","doi-asserted-by":"crossref","unstructured":"Clemens E, van der Kooi AL, Broer L, van Dulmenden Broeder E, Visscher H, Kremer L, et al. The influence of genetic variation on late toxicities in childhood cancer survivors: A review. Crit Rev Oncol Hematol 2018;126:154-67.","DOI":"10.1016\/j.critrevonc.2018.04.001"},{"key":"2026091912311761058_j_jcas.v6i2.351_ref_043","doi-asserted-by":"crossref","unstructured":"Clemens E, Meijer AJ, Broer L, Langer T, van der Kooi AL, Uitterlinden AG, et al. Genetic determinants of ototoxicity during and after childhood cancer treatment: Protocol for the pancarelife study. JMIR Res Protoc 2019;8:e11868.","DOI":"10.2196\/11868"},{"key":"2026091912311761058_j_jcas.v6i2.351_ref_044","doi-asserted-by":"crossref","unstructured":"Van der Kooi AL, Clemens E, Broer L, Zolk O, Byrne J, Campbell H, et al. Genetic variation in gonadal impairment in female survivors of childhood cancer: A pan care life study protocol. BMC Cancer 2018;18:930.","DOI":"10.1186\/s12885-018-4834-3"},{"key":"2026091912311761058_j_jcas.v6i2.351_ref_045","doi-asserted-by":"crossref","unstructured":"Zheng DJ, Sint K, Mitchell HR, Kadan-Lottick NS. Patterns and predictors of survivorship clinic attendance in a population-based sample of pediatric and young adult childhood cancer survivors. J Cancer Surviv 2016;10:505-13.","DOI":"10.1007\/s11764-015-0493-4"},{"key":"2026091912311761058_j_jcas.v6i2.351_ref_046","doi-asserted-by":"crossref","unstructured":"Klosky JL, Cash DK, Buscemi J, Lensing S, Garces-Webb DM, Zhao W, et al. Factors influencing long-term follow-up clinic attendance among survivors of childhood cancer. J Cancer Surviv 2008;2:225-32.","DOI":"10.1007\/s11764-008-0063-0"}],"container-title":["Journal of Cancer and Allied Specialties"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sfu.ca\/jcas\/index.php\/jcas\/article\/download\/351\/425","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/reference-global.com\/pdf\/10.37029\/jcas.v6i2.351","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T12:46:34Z","timestamp":1789821994000},"score":1,"resource":{"primary":{"URL":"https:\/\/reference-global.com\/article\/10.37029\/jcas.v6i2.351"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,1]]},"references-count":46,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,7,6]]},"published-print":{"date-parts":[[2020,7,1]]}},"alternative-id":["10.37029\/jcas.v6i2.351"],"URL":"https:\/\/doi.org\/10.37029\/jcas.v6i2.351","relation":{},"ISSN":["2411-989X"],"issn-type":[{"value":"2411-989X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,1]]}}}